medicationNot FDA-approvedPrescription only (US)Naltrexone is FDA-approved at 50 mg for opioid and alcohol dependence; low-dose use is off-label and compoundedBlocks opioid analgesia
Low-Dose NaltrexoneBenefits, Dosage & Interactions
Also known as: LDN
Low-Dose Naltrexone (LDN) refers to the off-label use of naltrexone at significantly lower doses than those approved by the U.S. Food and Drug Administration (FDA) for treating opioid and alcohol dependence. It is typically taken in the evening. The reported plasma half-life is about 4 hours, which shapes dosing frequency.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 1 human randomized trial published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
1 human randomized trial published.
Plasma half-life
~4 h
Typical timing
bedtime
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Low-Dose Naltrexone in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Low-Dose Naltrexone entry is written from. Each number matches an inline marker above.
- [1]Efficacy of Low-Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12-Month Randomised, Double-Blind, Placebo-Controlled TrialRodríguez-Freire C, et al. · European Journal of Pain · 2026 · Peer-reviewed · PMID 42385209
- [2]Low-Dose Naltrexone: What is the Evidence? A Narrative ReviewGouda AHK, et al. · Advances in Therapy · 2026 · Peer-reviewed · PMID 42060160
How to track Low-Dose Naltrexone doses
Tracking Low-Dose Naltrexone well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Low-Dose Naltrexone with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is bedtime. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Low-Dose Naltrexone through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 4 h, effects and timing shifts show up over days rather than instantly. Review Low-Dose Naltrexone alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
What is Low-Dose Naltrexone?
Low-Dose Naltrexone (LDN) refers to the off-label use of naltrexone at significantly lower doses than those approved by the U.S. Food and Drug Administration (FDA) for treating opioid and alcohol dependence. While standard naltrexone doses typically range from 50 mg to 300 mg daily, LDN doses are usually between 0.5 mg and 4.5 mg. The exact mechanisms through which LDN exerts its effects are not fully understood, but current hypotheses involve its temporary blockade of opioid receptors, leading to a compensatory upregulation of endogenous opioid production and receptor sensitivity.
Naltrexone is an opioid antagonist, meaning it blocks opioid receptors in the brain and body. At standard doses, this action is sustained, preventing exogenous opioids from binding and reducing cravings for alcohol. At very low doses, however, this blockade is believed to be transient, typically lasting only a few hours. This brief blockade is thought to trigger adaptive responses in the body, which may include modulation of the immune system and anti-inflammatory effects. LDN has garnered interest for its potential application in a range of conditions, particularly those involving immune system dysfunction, chronic pain, and certain neurological disorders.
It is important to emphasize that LDN is an off-label use of naltrexone, meaning that while naltrexone itself is an FDA-approved drug, its use at these low doses for conditions other than opioid or alcohol dependence is not specifically approved by the FDA. Prescribing clinicians typically require specialized knowledge and justification for its use in these contexts. (FDA Naltrexone Label, DrugBank)
What does the research say about Low-Dose Naltrexone?
Tap a section to expand.
The proposed mechanism of action for Low-Dose Naltrexone (LDN) differs significantly from that of standard-dose naltrexone. Naltrexone is a non-selective opioid receptor antagonist, primarily blocking mu-opioid receptors, but also delta and kappa-opioid receptors to a lesser extent. At standard doses (e.g., 50 mg), naltrexone provides a sustained blockade of opioid receptors, which is therapeutically used to prevent the euphorigenic effects of exogenous opioids and to reduce cravings in alcohol dependence.
In the context of LDN (typically 0.5 mg to 4.5 mg), the opioid receptor blockade is thought to be transient and incomplete. This brief, temporary blockade is hypothesized to occur typically for a few hours. This transient blockade is believed to lead to a rebound effect or compensatory upregulation of endogenous opioid production (such as endorphins and enkephalins) and an increase in the sensitivity of opioid receptors over time. These endogenous opioids play crucial roles in pain modulation, immune system regulation, and cellular growth.
Beyond opioid receptor modulation, LDN is also hypothesized to exert its effects through interactions with glial cells in the central nervous system. Glial cells, particularly microglia, contribute to neuroinflammation and pain sensitization. LDN is thought to inhibit the activity of Toll-like receptor 4 (TLR4) on microglia. By inhibiting TLR4, LDN may reduce the release of pro-inflammatory cytokines, thereby mitigating neuroinflammation and chronic pain. This dual mechanism – modulation of endogenous opioids and glial cell activity – forms the basis for LDN's studied effects in various conditions (Examine.com, PubChem).
Low-Dose Naltrexone (LDN) has been studied for its potential benefits across a variety of conditions, particularly those characterized by chronic inflammation, immune dysregulation, or pain. It is important to note that much of the evidence for these uses is still emerging and often comes from small clinical trials, case series, or observational studies. Its use is considered off-label for these applications.
* **Autoimmune Diseases:** LDN has been investigated in conditions like Crohn's disease, multiple sclerosis (MS), and Hashimoto's thyroiditis. In Crohn's disease, some studies suggest that LDN may help reduce disease activity and improve quality of life, potentially by modulating gastrointestinal inflammation and immune responses (Cochrane Review on LDN for Crohn's). For MS, early research has explored its potential to reduce spasticity and fatigue, possibly through its anti-inflammatory effects in the central nervous system (NIH ODS).
* **Chronic Pain Conditions:** Fibromyalgia and complex regional pain syndrome (CRPS) are areas where LDN has drawn interest. Studies in fibromyalgia suggest that LDN may help reduce pain and improve quality of life, possibly by modulating central nervous system pain pathways and reducing neuroinflammation (Examine.com). Its potential in CRPS is less established but is under investigation.
* **Certain Cancers:** Emerging laboratory and preliminary human studies have explored LDN's potential role as an adjunctive therapy in some cancers. This area of research is highly experimental and requires much more investigation before any conclusive statements can be made. The proposed mechanisms involve modulating cellular proliferation and immune responses.
* **Mental Health Conditions:** There is limited early research exploring LDN's potential in certain mood disorders or conditions related to chronic stress, hypothesized to involve its neuromodulatory effects.
It is crucial to understand that while these areas show promise, the evidence base is not as robust as for FDA-approved treatments for these conditions. Individual responses to LDN can vary significantly, and its use should be part of a comprehensive treatment plan under the supervision of a licensed clinician. (MedlinePlus, Mayo Clinic)
The evidence supporting the use of Low-Dose Naltrexone (LDN) for various conditions is considered emerging and of varying quality across different indications. While standard naltrexone is FDA-approved for opioid and alcohol dependence at higher doses, the use of LDN for other conditions is off-label and relies on a growing body of research, much of which is still in early stages. It is essential to differentiate between anecdotal reports, small pilot studies, and larger, multi-center randomized controlled trials.
For **Crohn's disease**, a systematic review and meta-analysis of randomized controlled trials (e.g., published in the *Journal of Clinical Gastroenterology*) have indicated that LDN may be efficacious for inducing clinical response and remission in active Crohn's disease without a significant increase in adverse events. These studies, while promising, often involve relatively small patient cohorts.
In **multiple sclerosis (MS)**, some randomized, double-blind, placebo-controlled crossover studies (e.g., from institutions like the University of California, San Francisco) have explored LDN's effects on symptoms like spasticity and fatigue. While some studies have shown modest improvements in certain patient-reported outcomes, the overall impact on disease progression or other objective measures is not yet definitively established. Research continues to investigate its potential role as a symptomatic treatment rather than a disease-modifying one.
For **fibromyalgia**, several randomized controlled trials (e.g., published in *Pain* journal) have suggested reductions in pain intensity and improvements in quality of life in patients receiving LDN compared to placebo. The documented effect sizes are typically moderate, and responses vary among individuals. These findings hint at LDN's potential as an adjunct therapy for chronic pain conditions.
Evidence for LDN in other conditions like autoimmune thyroiditis, certain cancers, or other chronic pain syndromes is generally less robust, often consisting of case reports, observational studies, or open-label trials. These studies can generate hypotheses but do not provide the same level of evidence as well-designed, large-scale randomized controlled trials. Across all studied conditions, LDN has generally been reported to have a favorable safety profile compared to many other treatments for these chronic diseases. However, the exact subset of patients most likely to benefit from LDN remains a subject of ongoing research, and its integration into standard medical practice for these conditions is still evolving. (Cochrane, Examine.com)
Low-Dose Naltrexone (LDN) is generally considered to have a favorable safety profile and is often well-tolerated, especially when compared to side effects associated with higher-dose naltrexone or other medications used for chronic conditions. However, side effects can occur, particularly when initiating treatment or during dose adjustments.
Commonly reported side effects include:
* **Sleep disturbances:** The most frequently reported side effect is sleep disruption, which can manifest as vivid dreams, nightmares, or difficulty falling asleep. This typically occurs in the early stages of treatment and often subsides with continued use. Taking LDN in the morning may help mitigate this issue for some individuals.
* **Gastrointestinal effects:** Some individuals may experience mild nausea, abdominal cramps, or changes in bowel habits (constipation or diarrhea), particularly when first starting LDN.
* **Headache:** Mild headaches can occur.
* **Fatigue or drowsiness:** While less common than sleep disturbances, some individuals may experience temporary fatigue or drowsiness.
Less common side effects may include:
* Anxiety or irritability.
* Temporary mood changes.
* Rarely, mild skin rashes.
These side effects are typically mild and transient. If side effects persist or are bothersome, a clinician may suggest adjusting the dose or timing of administration. Serious adverse events are rare with LDN. Because naltrexone modulates opioid receptors, there is a theoretical concern regarding its use in individuals on chronic opioid medication, even at low doses, due to the risk of precipitating withdrawal symptoms (see *Do Not Mix* section). Regular monitoring and communication with a prescribing clinician are important to manage any potential side effects. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
When considering Low-Dose Naltrexone (LDN), several warnings and precautions are important due to its mechanism of action and the off-label nature of its use for many conditions.
* **Opioid Use:** LDN is an opioid antagonist. While the doses are very low, there is a risk of precipitating acute opioid withdrawal syndrome in individuals who are currently taking opioid medications, including prescription pain relievers, illicit opioids, or even opioid-containing cough medicines or antidiarrheals. This risk extends to those who have recently used opioids, as naltrexone can displace opioids from receptors. A sufficient washout period from opioids is typically recommended before initiating LDN, with specific durations depending on the type and half-life of the opioid used.
* **Liver Function:** Although standard-dose naltrexone carries a black box warning for hepatotoxicity, particularly with very high doses (e.g., 300 mg daily or more), there is no evidence to suggest that LDN doses (0.5 mg to 4.5 mg) pose a significant risk of liver damage. However, patients with pre-existing severe liver disease should be monitored or use with caution at the discretion of their clinician (FDA Naltrexone Label).
* **Thyroid Conditions:** In individuals with autoimmune thyroid conditions like Hashimoto's, starting LDN may, in some cases, temporarily fluctuate thyroid hormone levels or necessitate adjustments in thyroid medication dosages. Close monitoring of thyroid function tests by a clinician is advisable.
* **Immunosuppression:** Because LDN is thought to modulate immune function, caution is advised for individuals who are immunosuppressed or receiving other immunosuppressive therapies, or those with certain active infections. The full implications of immune modulation at these low doses are still being studied.
* **Surgery:** Patients undergoing surgery should inform their surgical team about LDN use, especially if opioid pain relief is anticipated post-operatively. LDN may interfere with the effectiveness of opioid analgesics.
* **Pregnancy and Breastfeeding:** There is limited safety data on the use of naltrexone, including LDN, during pregnancy and breastfeeding. Therefore, it is generally advised to avoid its use unless the potential benefits clearly outweigh the potential risks, and this decision should be made in consultation with a healthcare provider.
* **Individual Variability:** Responses to LDN can be highly individual. What works for one person may not work for another, and side effects can also vary. Dosing and titration should be carefully managed by a clinician.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Low-Dose Naltrexone (LDN) is specifically contraindicated in certain situations due to the risk of serious adverse events. Understanding these contraindications is crucial for safe prescribing and use.
* **Current Opioid Use:** The most absolute contraindication for LDN is current reliance on opioid pain medication. Naltrexone, even at low doses, is an opioid receptor antagonist. Administering LDN to someone who is physically dependent on opioids will precipitate an immediate and severe opioid withdrawal syndrome, which can be extremely distressing and potentially dangerous. This includes prescription opioids for pain management, opioid-containing cough or diarrhea medications, and illicit opioids. A sufficient opioid-free period (washout) is required before initiating LDN, the duration of which depends on the specific opioid used and its half-life (e.g., typically 7-14 days for long-acting opioids).
* **Acute Hepatitis or Liver Failure:** While LDN itself is not commonly associated with hepatotoxicity, standard-dose naltrexone carries a warning for liver damage, particularly at very high doses. However, in patients with active or severe liver disease, especially acute hepatitis or liver failure, naltrexone metabolism could be impaired, and its use is contraindicated. Regular monitoring of liver function tests is generally advised, though not strictly required for LDN due to the low dose.
* **Allergy or Hypersensitivity:** A known allergy or hypersensitivity to naltrexone or any component of its formulation is a contraindication.
These contraindications are in place to prevent severe adverse reactions and ensure patient safety. Any individual considering LDN should undergo a thorough medical evaluation by a licensed clinician to rule out these contraindications and assess overall suitability for treatment. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Low-Dose Naltrexone (LDN) should not be mixed or used concurrently with certain substances due to potential drug interactions or counteracting effects.
* **Opioid Medications:** This is the most critical interaction. Simultaneous use of LDN with any opioid pain medication (e.g., tramadol, codeine, oxycodone, hydrocodone, morphine, fentanyl) or opioid-containing medications (e.g., certain cough suppressants or anti-diarrheals like Lomotil containing diphenoxylate) is strictly contraindicated. LDN will block opioid receptors, displacing any existing opioids and precipitating acute opioid withdrawal syndrome in physically dependent individuals. For individuals taking opioids, a careful washout period (typically 7-14 days, depending on the opioid) is required before starting LDN. Additionally, patients on LDN who require acute pain management with opioids (e.g., after surgery or injury) may find that opioids are less effective or require higher doses, necessitating careful communication with their medical team.
* **Immunosuppressants (Specific Types):** While LDN is thought to modulate the immune system, its interaction with potent immunosuppressive drugs (e.g., corticosteroids in high doses, biologics for autoimmune disease, post-transplant medications) is not fully characterized. There is a theoretical concern that LDN's immune-modulating effects could interfere with or be counteracted by these medications. Close monitoring by a clinician is important, and concurrent use may require dose adjustments of either medication.
* **Other Medications Affecting Liver Metabolism (CYP450):** Naltrexone is metabolized in the liver, primarily by the CYP2B6 enzyme system. While LDN is used at very low doses, caution is advised when co-administering with drugs that are strong inhibitors or inducers of CYP2B6, as this could theoretically alter naltrexone's plasma concentrations. However, due to the low dose, clinically significant interactions are generally considered less likely than with standard-dose naltrexone.
* **Alcohol:** While naltrexone at higher doses is used to treat alcohol dependence, there is no strong evidence to suggest that LDN interacts negatively with moderate alcohol consumption. However, given individual variability, excessive alcohol intake while on any medication is generally discouraged.
Patients should always provide a comprehensive list of all medications, supplements, and illicit substances they are taking to their clinicians before initiating LDN to identify any potential interactions. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for taking Low-Dose Naltrexone (LDN) is often at bedtime, primarily based on the hypothesis that the transient opioid receptor blockade at night could best upregulate endogenous opioid production during the body's natural circadian rhythm. This timing has been historically favored among clinicians prescribing LDN.
However, some individuals experience sleep disturbances, such as vivid dreams, nightmares, or insomnia, when taking LDN at night. In such cases, a clinician may recommend taking LDN in the morning. Taking LDN in the morning may help to mitigate sleep-related side effects without necessarily compromising its therapeutic effects, although the optimal timing to maximize benefits is not definitively established and may vary by individual and condition.
LDN can be taken either with or without food. There are no strict food-related restrictions, though taking it with a small meal might help reduce any mild gastrointestinal discomfort that some individuals experience when first starting the medication.
What interacts with Low-Dose Naltrexone?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
Frequently asked questions about Low-Dose Naltrexone
Naltrexone is an FDA-approved medication used at higher doses (typically 50 mg or more) to treat opioid and alcohol dependence by providing a sustained blockade of opioid receptors. Low-Dose Naltrexone (LDN) refers to the off-label use of naltrexone at much lower doses (typically 0.5 mg to 4.5 mg) for various conditions, primarily chronic pain and autoimmune diseases. At these low doses, its mechanism is believed to involve a transient opioid receptor blockade, leading to a compensatory increase in endogenous opioids and modulation of the immune system, which differs from its action at high doses (DrugBank, Examine.com).
Naltrexone itself is FDA-approved for opioid and alcohol dependence at standard doses. However, the use of naltrexone at low doses (LDN) for conditions such as autoimmune diseases or chronic pain is considered an off-label use. This means that while licensed clinicians can prescribe it, it is not specifically approved by the FDA for these indications, and research is ongoing (FDA Naltrexone Label).
The time it takes for LDN to show effects can vary significantly depending on the individual and the condition being treated. Some individuals may report subtle improvements in energy or sleep within a few weeks, while for others, noticeable benefits, especially in chronic pain or autoimmune conditions, may take several months (e.g., 3-6 months) of consistent use. Clinicians often advise patience and ongoing monitoring to assess efficacy.
No, it is critically important to not take LDN if you are currently using opioid pain medication (prescription or illicit). Naltrexone, even at low doses, is an opioid antagonist and will block opioid receptors, potentially precipitating an immediate and severe opioid withdrawal syndrome. A specific opioid-free washout period, determined by a clinician, is required before starting LDN if you have been taking opioids (Mayo Clinic).
The most common side effects reported with LDN are generally mild and transient, especially upon initiation. These include sleep disturbances like vivid dreams or insomnia, and occasionally mild gastrointestinal upset or headache. These often subside over time, or can be managed by adjusting the dose or timing of administration with clinician guidance (Examine.com).
Low-Dose Naltrexone is a medication, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Low-Dose Naltrexone is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 4 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Low-Dose Naltrexone with no sign-up.
Combining a medication like Low-Dose Naltrexone with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Low-Dose Naltrexone: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 4 hours is why protocols often split Low-Dose Naltrexone across the day rather than using a single dose. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Low-Dose Naltrexone clears quickly (plasma half-life around 4 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Low-Dose Naltrexone the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Low-Dose Naltrexone?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review(opens PubMed in a new tab)Curr Pain Headache Rep · 2020 · PMID 32845365 · https://pubmed.ncbi.nlm.nih.gov/32845365/
- 2.Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy(opens PubMed in a new tab)Int Immunopharmacol · 2018 · PMID 29885638 · https://pubmed.ncbi.nlm.nih.gov/29885638/
- 3.The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain(opens PubMed in a new tab)Clin Rheumatol · 2014 · PMID 24526250 · https://pubmed.ncbi.nlm.nih.gov/24526250/
- 4.Low-dose naltrexone for treatment of dermatologic conditions: A clinical review(opens PubMed in a new tab)J Am Acad Dermatol · 2026 · PMID 40962192 · https://pubmed.ncbi.nlm.nih.gov/40962192/
Verify at
Publisher search links for Low-Dose Naltrexone. These are places to check the information — they are not citations, so they are not numbered.
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Low-Dose Naltrexone?
Plain-text summary, safe to quote verbatim:
Low-Dose Naltrexone (LDN) refers to the off-label use of naltrexone at significantly lower doses than those approved by the U.S. Food and Drug Administration (FDA) for treating opioid and alcohol dependence. It is typically taken in the evening. The reported plasma half-life is about 4 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/low-dose-naltrexone
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Low-Dose Naltrexone — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/low-dose-naltrexone
What compounds are similar to Low-Dose Naltrexone?
Others in the medication category or studied for the same goals.